BITESIZE: New GLP-1 Study Raises Metabolic Health Questions

Do GLP-1 medications improve metabolic health as much as they support weight loss? A new observational study in the Annals of Internal Medicine raises an important question about semaglutide, insulin discontinuation, type 2 diabetes, and what meaningful metabolic improvement may require.In this episode of Metabolic Mind, Dr. Bret Scher breaks down a real-world study of more than 9,000 veterans with type 2 diabetes who were using insulin and then added either a GLP-1 receptor agonist, SGLT2 inhibitor, or DPP4 inhibitor. Despite semaglutide’s stronger association with weight loss, the study found similar insulin discontinuation rates across all three groups over three years.Dr. Scher covers:Why weight loss and metabolic health improvements may not always move togetherWhat insulin discontinuation can reveal about insulin resistance and beta cell functionWhy semaglutide did not outperform older diabetes medications in this studyThe limitations of observational research and real-world medication dataHow GLP-1 medications and therapeutic carbohydrate reduction may work through complementary mechanismsWhy combining GLP-1s with therapeutic carbohydrate reduction may be an important area for future research and clinical practiceThis conversation takes a closer look at what metabolic health means, and why the path from weight loss to insulin independence may be more complex than the scale alone can show.👉 Want to stay up to date with the latest research on metabolic health and metabolic psychiatry? Sign up for our newsletter to stay informed: metabolicmind.org/about-us/newsletter/🔎 Have questions about how to apply metabolic therapies effectively? Submit them at metabolicmind.org/questions to be featured in a future Metabolic Mailbag episode.#MetabolicMind #KetogenicTherapy #GLP1Expert Featured:Bret Scher, MD - Baszucki Group Medical Director & Host of the Metabolic Mind Podcasthttps://www.linkedin.com/in/bret-scher-08baaa102/https://www.instagram.com/drscher858/?hl=enhttps://x.com/bschermdResources Mentioned:Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulationhttps://www.acpjournals.org/doi/10.7326/ANNALS-25-05216Free CME Clinician Trainings:Are you a clinician who would like to learn more about the science behind these therapies and how to implement them in practice? Earn CME with our growing library of courses from some of the top experts in the field including Dr. Chris Palmer, Dr. Georgia Ede, Dr. Matthew Bernstein, Dr. Mariela Glandt, Dr. Deanna Kelly, Dr. Julie Milder, Dr. Zoltan Sarnyai, and Dr. Bret Scher with more coming soon.Our courses have been made FREE by grants from Baszucki Group, so we can spread these powerful therapies as widely as possible. Earn CME/CNE credits: https://www.metabolicmind.org/for-clinicians/trainings-courses/?utm_medium=organic-social&utm_source=youtube&utm_campaign=cme-ytFollow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry.Learn more about metabolic psychiatry and find helpful resources at https://metabolicmind.org/About us:Metabolic Mind is a non-profit initiative of Baszucki Group working to transform the study and treatment of mental disorders by exploring the connection between metabolism and brain health. We leverage the science of metabolic psychiatry and personal stories to offer education, community, and hope to people struggling with mental health challenges and those who care for them.Our channel is for informational purposes only. We are not providing individual or group medical or healthcare advice nor establishing a provider-patient relationship. Many of the interventions we discuss can have dramatic or potentially dangerous effects if done without proper supervision. Consult your healthcare provider before changing your lifestyle or medications.